Surmountable Caregiver Barriers to Paratonia Treatment in Community-Dwellers with Dementia: A Cross-Sectional Survey
Paratonia is an involuntary, variable resistance to passive movement that affects 90%-100% of patients with advanced dementia, interferes with care and contributes to caregiver burden. Botulinum toxin A is a candidate treatment but has no approved indication, and whether community-dwelling caregivers would attend quarterly outpatient treatment has not been characterised. In an online survey of 274 caregivers, 65.3% reported the care-recipient's paratonia exerted a moderate to extreme impact on their own physical, emotional and mental well-being, and 84.6% reported they would attend an outpatient clinic if treatment were effective. Caregiver willingness suggests the feasibility of clinic-based treatment models.
Authors
- Galit Kleiner (ORCID: https://orcid.org/0000-0001-5261-2509)
- Jessica Cuppage
- Graham Flick (ORCID: https://orcid.org/0000-0001-9183-4040)
- Adriana Shnall (ORCID: https://orcid.org/0009-0002-9014-4464)
- Giulia Perri
- Stephanie Omonibo
Institutions
- University of Toronto (CA)
- Baycrest Hospital (CA)
- Baycrest Academy for Research and Education (CA)
Publication Details
- Journal
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Published
- 2026-09-25
- DOI
- https://doi.org/10.1017/cjn.2026.10687
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00